BYVASDA®: Bevacizumab Injection
Products
Information
Received NMPA marketing approval on Jun 19, 2020
Approved for advanced non-small cell lung cancer and metastatic colorectal cancer, adult recurrent glioblastoma, hepatocellular carcinoma, cervical cancer, ovarian cancer.
A total of 8 indications have been approved and included in the NRDL